ALPHARETTA, Ga.--(BUSINESS WIRE)--
Clearside Biomedical, Inc., announces the U.S. Patent and Trademark
Office (USPTO) granted U.S. Patent Application No. 13/447,246 as U.S.
Patent No. 8,808,225 in a patent titled, "Methods and Devices for Drug
Delivery to Ocular Tissue Using Microneedle." This is the fourth patent
allowance in the U.S. related to its proprietary microneedle drug
delivery methods and devices.
U.S. Patent No. 8,808,225 provides exclusivity for the administration of
any drug to an eye of a patient by inserting a hollow microneedle into
the patient’s eye and infusing the drug into the suprachoroidal space of
the patient’s eye. The patent, exclusively licensed to Clearside, is the
fourth generated from Clearside’s alliance with the Georgia Tech
Research Corporation and Emory University.
In April 2011, June 2012 and January 2014, the USPTO issued method and
device patents covering the Company's drug delivery methods and devices
for carrying out the methods.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a
clinical-stage biopharmaceutical company developing first-in-class drug
therapies to treat chronic, blinding diseases of the eye. Clearside’s
product candidates focus on diseases affecting the retina and the
choroid, especially diseases associated with macular edema, and are
injected non-surgically into the suprachoroidal space with Clearside’s
proprietary microinjector. Visit www.clearsidebio.com
for more information.
Clearside Biomedical, Inc.
Charles Deignan, 678-270-4005
Source: Clearside Biomedical, Inc.